MedTrace Logo

Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

NCT03387605 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-05-23

No results posted yet for this study

Summary

This is a randomized, double blind, single center trial to study of the effects of Ivabradine vs. Placebo on patients hospitalized for Stage D heart failure (HF)/ and cardiogenic shock (CS) who will require continuous infusion of Dobutamine and have developed sinus tachycardia (ST) (heart rate \>100 beats/min).

The aim of the study will be to assess the potential of Ivabradine to slow ST and improve hemodynamics in patients with stage D HF/CS on Dobutamine treatment.

Conditions

Interventions

DRUG

Ivabradine

ivabradine or placebo given orally 2 times daily for 72 hours

DRUG

Placebo

matching placebo given 2 times daily for 72 hours

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Loyola University

    lead OTHER

Principal Investigators

  • Eugenia Raichlin, MD · Loyola University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2020-01-31
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03387605 on ClinicalTrials.gov